Biome Australia Limited announced that recruitment for the Biome LiftTM Probiotic clinical trial (the "trial") taking place at La Trobe University in Melbourne has surpassed the sample size calculation target of 40 participants. The double-blind placebo-controlled trial has successfully recruited the target 40 patients, whose successful participation in the trial will see them dosed once per day over a three-month period. Participants in the trial, who each demonstrate symptoms consistent with subthreshold depression, will be divided into two cohorts, with one cohort receiving Biome LiftTM and the other receiving a placebo.

Preliminary results are expected in Third Quarter fiscal year 2023. The trial will be measuring a number of outcomes including (but not limited to) depression, anxiety, stress, gut microbiota composition and gastrointestinal symptoms. Biome LiftTM Probiotic is Biome's condition-specific probiotic product which contains a formulation previously shown to assist with depressive mood state, anger, fatigue and sleep quality in a healthy adult cohort in a study published in the Frontiers in Psychiatry in 20191.